ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders